Ypsomed is a medical technology company that specialises in drug delivery devices for self-injection, under the Yposmed Delivery Systems brand, and products for diabetic patients, under the mylife Diabetescare brand. Ypsomed develops a range of autoinjector, pen injector and wearable injector platforms.
Ypsomed is an independent developer and manufacturer of autoinjector and pen injector systems for self-administration of injectable drugs. The company provides customisable product platforms for autoinjectors for prefilled syringes in 1 mL and 2.25 mL format, disposable pens for 3 mL and 1.5 mL cartridges, reusable pens that include automated injection mechanisms, and injection devices for drugs in dual-chamber cartridges, such as lyophilised drugs. Click-on needles and infusion sets complement the company’s self-injection systems product portfolio. Ypsomed is
The company’s device offering includes:
- YpsoMate, VarioJect and LyoTwist autoinjectors
- ServoPen, YpsoPen, UnoPen and FixPen pen injectors
- YpsoDose wearable injector
- SmartPilot connected add-on.
Ypsomed has more than 35 years of experience working with pharma and biotech companies in the parenterals sector. The company is ISO13485 certified and all processes are run according to design control and cGMP guidelines. Ypsomed operates the mylife Diabetescare brand for marketing to patients and pharmacies, and the Ypsomed Delivery Systems brand for business-to-business operations. Ypsomed Group employs around 1500 people.